Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05248893 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 986
- Enrollment target
NCT05248893: Completed Phase 3 study, sponsored by AbbVie.
NCT05248893 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 986 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05248893, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 986 participants
- Enrollment target
Study Summary
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. The purpose of this study is to evaluate the safety of AGN-151586 over multiple repeat treatments of the study drug to improve the appearance of glabellar lines. AGN-151586 is an investigational product being developed for the treatment of GL. Around 940 to 1100 adult participants with moderate to severe GL will be enrolled in the study in approximately 45 sites in the United States. This is an open-label, 126 day study in which all participants will receive 5 intramuscular AGN-151586 injections to the glabellar complex on Day 1. Participants meeting retreatment criteria may receive up to 2 additional cycles of treatment during the study. Participants will attend regular visits during the study at a study site. The effect of the treatment will be checked by medical assessments, blood tests, telephone calls, questionnaires and checking for side effects.
Primary Outcome
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.
Interventions
- DRUG AGN-151586
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 986 participants |
| Start Date | 2022-02-25 |
| Est. Completion | 2023-06-26 |
| Phase | Phase 3 |
What the finished NCT05248893 record still lists
NCT05248893 is an interventional study that assigns participants to a tested intervention. The registered 986 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% higher).
The record links to 0 conditions, and to 1 intervention - of which AGN-151586 is the first listed.
NCT05248893 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05248893 about?
NCT05248893 is a clinical study titled "A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines". Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. The purpose of this study is to evaluate the safety of AGN-151586 over multiple repeat treatments of the ...
What is the current status of trial NCT05248893?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 986 participants. The study started on 2022-02-25. Estimated completion is 2023-06-26.
What interventions are being tested in trial NCT05248893?
The interventions under investigation include: AGN-151586 (DRUG).
Who is sponsoring clinical trial NCT05248893?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05248893's enrollment target sits among peer trials
986 320th of 2000 higher than 1,681 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05079841 · 988 participants · Phase 4
The Stimulation To Induce Mothers Study
- NCT05441709 · 990 participants · NA
Furthering Equity Through Infant Feeding EDucation and Support
- NCT06340646 · 990 participants · NA
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
- NCT06878261 · 990 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI